Insights from 2023 SABCS
L

SABCS 2023 Insights: "Comparison of NGS Results From the Cerebrospinal Fluid, Peripheral Blood, and Systemic Metastatic Tumor Tissue of Patients With mBC and LMD"

By Insights from 2023 SABCS FEATURING Laura Huppert
By Insights from 2023 SABCS FEATURING Laura Huppert
0 views
December 20, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

06:14
Lilly Medical Affairs

CDK4/6 Inhibitors as First-Line Treatment for HR+, HER2- MBC

Feat. J. O’Shaughnessy

Featured Video

03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri

Recommended

AUTOPLAY
25:08
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

Feat. S. Tolaney, H. Rugo
12:35
Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…

Feat. S. Tolaney, H. Rugo
36:18
Insights from ESMO Breast 2024 Annual Meeting

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

Feat. H. Rugo
06:10
Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Summary: "Is There a Role for Combining ADCs W…

Feat. S. Tolaney
49:07
SABCS 2022 Conference Coverage

SABCS 2022 Expert Panel Discussion: Practice-Changing Updates

Feat. J. O'Shaughnessy, S. Tolaney, S. Hurvitz, H. Rugo
07:50
Oncology Data Advisor

ESMO 2023 Insights: "Real-World Use Patterns, Effectiveness, &a…

Feat. K. Kalinsky
33:44
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Expert Recap: "Metastatic Breast Cancer Deep Dive &a…

Feat. S. Tolaney, H. Rugo
17:35
Insights from 2023 SABCS

SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…

Feat. P. Tarantino
10:09
Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Insights: "Pooled Analysis of T-DXd Retreatmen…

Feat. H. Rugo
05:35
Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Insights: "IMpassion132 Trial - Is There a Rol…

Feat. S. Tolaney
25:35
Total Health

NGS and Liquid Biopsy: Overcoming Challenges in Widespread Testing

Feat. S. Kazmi
21:37
Dana-Farber Cancer Institute

Standard Treatments for HR+/HER2- mBC in 2023

Feat. S. Sammons
09:26
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "DESTINY-Breast06 - T-DXd vs. Physician’s …

Feat. G. Curigliano
12:24
Stanford Medicine

HR+ mBC: CDK4/6i Progression Management

Feat. M. Dolezal
29:45
Miami Cancer Institute Precision Oncology Symposium

Precision Therapy for HR+/HER2- mBC

Feat. J. O'Shaughnessy
20:52
Total Health

Diagnostics in Lung Cancer: A Comprehensive Discussion - Best of Lun…

Feat. T. Boyle
12:37
University of Colorado Cancer Center

Young Women With HR+/HER2- Breast Cancer: Options for Risk Assessment

Feat. V. Borges
03:24
ecancer

SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…

Feat. V. Kaklamani
11:19
Adam Brufsky

HER2+ mBC: The Role of TDM-1

35:14
OncoAlert

Advanced TNBC Updates

Feat. H. Rugo